MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial
The trial was designed to enrol patients suffering from hormone receptor and HER-2-recepor negative breast cancer who have metastastatic disease. The trial recruited 135 patients divided into three groups: EndoTAG(TM)-1 alone, EndoTAG(TM)-1 in combination with a cytotoxic drug or the cytotoxic drug alone. The study will assess safety, tolerability and efficacy. The primary endpoint of the trial is progression-free survival after 16 weeks,.
Dr. Axel Mescheder, CSO & CDO of MediGene AG, commented: "The completion of patient recruitment in this important trial is another key milestone for MediGene which also shows the high degree of acceptance of this treatment among physicians and patients. It also ensures that we will be able to conclude the trial within the projected time frame. This controlled trial has been powered to allow the assessment of both the efficacy and the safety of EndoTAG(TM)-1 in this very difficult to treat cancer population."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.